Ticker >

Kilitch Drugs(India) share price

Kilitch Drugs (India) Ltd.

NSE: KILITCH BSE: 524500 SECTOR: Pharmaceuticals & Drugs  15k   16   1

340.30
-0.55 (-0.16%)
BSE: 17 May 04:01 PM

Price Summary

Today's High

₹ 344.05

Today's Low

₹ 340.3

52 Week High

₹ 469.85

52 Week Low

₹ 175

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

547.28 Cr.

Enterprise Value

551.18 Cr.

No. of Shares

1.61 Cr.

P/E

28.72

P/B

2.52

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  135.02

CASH

17.97 Cr.

DEBT

21.86 Cr.

Promoter Holding

69.23 %

EPS (TTM)

₹  11.85

Sales Growth

12%

ROE

8.59 %

ROCE

9.9%

Profit Growth

49.29 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year12%
3 Year24.68%
5 Year18.48%

Profit Growth

1 Year49.29%
3 Year52.21%
5 Year20.46%

ROE%

1 Year8.59%
3 Year6.25%
5 Year6.47%

ROCE %

1 Year9.9%
3 Year7.55%
5 Year8.04%

Debt/Equity

0.1147

Price to Cash Flow

89.75

Interest Cover Ratio

17.9250717953181

CFO/PAT (5 Yr. Avg.)

0.622410159458245

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 69.23 0
Dec 2023 69.23 0
Sep 2023 69.23 0
Jun 2023 68.25 0
Mar 2023 68.25 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 52.2095334914961% for the Past 3 years.
  • The company has shown a good revenue growth of 24.6815557785391% for the Past 3 years.
  • Company has a healthy Interest coverage ratio of 17.9250717953181.
  • Company’s PEG ratio is 0.582584603772622.
  • The company has an efficient Cash Conversion Cycle of -19.2325175715715 days.
  • Company has a healthy liquidity position with current ratio of 2.03419256381306.
  • The company has a high promoter holding of 69.23%.

 Limitations

  • Company has a poor ROE of 6.25369281875601% over the past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 28.5 43.28 31.13 31.57 29.77
Total Expenditure 24.29 36.6 25.89 25.86 25.75
Operating Profit 4.22 6.69 5.24 5.72 4.02
Other Income 1.11 1.43 0.98 0.92 3.4
Interest 0.28 0.41 0.38 0.43 0.54
Depreciation 0.38 0.37 0.26 0.28 0.3
Exceptional Items 0 0 0 0 0
Profit Before Tax 4.67 7.34 5.58 5.93 6.58
Tax 0.74 2.21 1.39 1.69 1.08
Profit After Tax 3.93 5.13 4.19 4.24 5.5
Adjusted EPS (Rs) 2.52 3.29 2.69 2.64 3.42

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 96.42 60.77 70.02 105.16 117.78
Total Expenditure 80.82 59.6 64.69 94.03 100.45
Operating Profit 15.6 1.17 5.33 11.13 17.34
Other Income 5.78 6.14 4.19 4.56 4.6
Interest 0.65 0.93 0.88 0.8 1.15
Depreciation 1.2 1.15 1.14 0.96 1.34
Exceptional Items 0 0 0 0 0
Profit Before Tax 19.52 5.22 7.51 13.93 19.45
Tax 4.76 0.77 1.35 3.4 3.73
Net Profit 14.77 4.46 6.16 10.53 15.72
Adjusted EPS (Rs.) 9.62 2.89 3.97 6.76 10.09

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 15.36 15.43 15.49 15.58 15.58
Total Reserves 135.73 136.21 147.44 162.45 180.35
Borrowings 0 0 0 0 0
Other N/C liabilities -0.62 -0.57 -0.89 -1.23 -1.91
Current liabilities 20.53 22.08 32.53 53.99 56.42
Total Liabilities 171 173.15 194.57 230.79 250.44
Assets
Net Block 7.82 7.67 6.94 14.18 15.08
Capital WIP 0 0 0 0 1.31
Intangible WIP 0 0 0 0 0
Investments 71.24 70.27 70.1 70.15 71.1
Loans & Advances 27.73 38.66 44 46.6 48.17
Other N/C Assets 0 0.54 1.76 2.14 0.02
Current Assets 64.21 56.02 71.76 97.72 114.77
Total Assets 171 173.15 194.57 230.79 250.44
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 19.52 5.22 7.51 13.93 19.45
Adjustment -2.81 -4.4 -0.46 0.1 1.95
Changes in Assets & Liabilities -5.12 8.71 0.09 -6.28 -10.97
Tax Paid -4.18 -2.25 -1.01 -2.54 -4.33
Operating Cash Flow 7.42 7.29 6.13 5.21 6.1
Investing Cash Flow -21.9 -10.08 -5.35 -16.08 6.24
Financing Cash Flow 14.69 1.44 2.27 7.55 3.04
Net Cash Flow 0.2 -1.35 3.05 -3.32 15.39

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 68.25 68.25 69.23 69.23 69.23
bhavin mukund mehta 19.99 19.99 20.92 20.92 20.92
kilitch company (pharma) ... 42.54 42.54 41.22 41.22 41.22
mukund mehta 5.72 5.72 7.09 7.09 7.09
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 31.75 31.75 30.77 30.77 30.77
dipak kanayalal shah 3.08 3.08 3.11 - 3.11
investor education and pr... - - - - 1.45
sherni shares limited - - - - 1.05
dipak kanaylal shah - - - 3.11 -
investor education and pr... 1.50 1.50 1.46 1.45 -
llp - - 0.09 0.10 -

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Company News

Kilitch Drugs (India) informs about loss of share certificate18 May 2024, 12:38PM Kilitch Drugs (India) informs about details of loss of certificate18 May 2024, 12:19PM Kilitch Drugs (India) informs about annual secretarial compliance14 May 2024, 5:27PM Kilitch Drugs (India) informs about issuance of duplicate share certificate28 Feb 2024, 3:24PM Kilitch Drug’s arm secures tender worth $9.13 million26 Feb 2024, 4:00PM Kilitch Drugs (India) informs about loss of share certificate17 Feb 2024, 3:44PM Kilitch Drugs(India) - Quaterly Results8 Feb 2024, 6:00PM Kilitch Drugs(India) - Quaterly Results8 Feb 2024, 6:00PM Kilitch Drugs (India) informs about details of loss of certificate 18 Dec 2023, 5:09PM Kilitch Drugs(India) - Quaterly Results11 Aug 2023, 1:55PM Kilitch Drugs (India) informs about outcome of board meeting22 Jul 2023, 3:20PM Kilitch Drugs (India) informs about certificate 17 Jul 2023, 12:08PM Kilitch Drugs (India) informs about loss of share certificate23 Jun 2023, 2:50PM Kilitch Drugs(India) - Quaterly Results29 May 2023, 6:09PM Kilitch Drugs (India) informs about newspaper publication20 Mar 2023, 5:07PM Kilitch Drugs(India) - Quaterly Results26 May 2022, 6:16PM Kilitch Drugs (India) informs about disclosure23 Apr 2022, 10:25AM Kilitch Drugs (India) informs about press release4 Mar 2022, 4:25PM Kilitch Drugs acquires land to establish green field pharma complex3 Mar 2022, 5:29PM Kilitch Drugs India informs about compliance certificate11 Oct 2021, 4:08PM Kilitch Drugs starts production of Cephalosporin Injectables at Ethiopia Plant26 Jul 2021, 1:43PM Kilitch Drugs (India) informs about non-applicability of large corporate entity28 Apr 2021, 9:56AM Kilitch Drugs’ arm gets manufacturing license to produce ‘Cephalosporin’19 Dec 2020, 10:45AM

Kilitch Drugs(India) Stock Price Analysis and Quick Research Report. Is Kilitch Drugs(India) an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Kilitch Drugs(India) and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Kilitch Drugs(India) cash from the operating activity was Rs 6.0976 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Kilitch Drugs(India) has a Debt to Equity ratio of 0.1147 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Kilitch Drugs(India) , the EPS growth was 49.2939818241023 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Kilitch Drugs(India) has OPM of 14.7195490030437 % which is a bad sign for profitability.
     
  • ROE: Kilitch Drugs(India) have a poor ROE of 8.59447218168948 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Kilitch Drugs(India) is Rs 341.3. One can use valuation calculators of ticker to know if Kilitch Drugs(India) share price is undervalued or overvalued.
Last Updated on:
Brief about Kilitch Drugs(India)
X